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Glial cell line–derived neurotrophic factor (GDNF) is a
growth factor that regulates the health and function of neurons
and other cells. GDNF binds to GDNF family receptor 1
(GFRa1), and the resulting complex activates the RET receptor
tyrosine kinase and subsequent downstream signals. This fea-
ture restrictsGDNFactivity to systems inwhichGFRa1 andRET
are both present, a scenario that may constrain GDNF breadth
of action. Furthermore, this co-dependence precludes the use of
GDNF as a tool to study a putative functional cross-talk between
GFRa1 and RET. Here, using biochemical techniques, terminal
deoxynucleotidyl transferase dUTP nick end labeling staining,
and immunohistochemistry in murine cells, tissues, or retinal
organotypic cultures, we report that a naphthoquinone/quino-
linedione family of small molecules (Q compounds) acts as RET
agonists. We found that, like GDNF, signaling through the
parental compound Q121 is GFRa1-dependent. Structural
modifications of Q121 generated analogs that activated RET
irrespective of GFRa1 expression. We used these analogs to
examine RET–GFRa1 interactions and show that GFRa1 can
influence RET-mediated signaling and enhance or diminish
AKTSer/Thr kinase or extracellular signal-regulated kinase sig-
naling in a biasedmanner. In a geneticmutantmodel of retinitis
pigmentosa, a lead compound, Q525, afforded sustained RET
activation and prevented photoreceptor neuron loss in the ret-
ina. This work uncovers key components of the dynamic rela-
tionships between RET and its GFRa co-receptor and provides
RET agonist scaffolds for drug development.
Naphthoquinones are structurally and biologically diverse
molecules of natural and synthetic origin that have been stud-
ied extensively as drug leads (1). The mechanisms of action are
quite varied, and the biological outcomes range on a spectrum,
with many variables governing the balance between cytotoxic-
ity and cytoprotection (2). Activities include wide and nonse-
lective inhibition of protein-tyrosine phosphatases (PTPs)2 (3),
but there are examples of selective PTP inhibition (4). Recent
work with the natural quinones shikonin (5) and plumbagin (6)
indicated that this class can generate a wide range of cytotoxic
or protective effects, from the regulation of inflammatory and
stress mediators such as TNF and pMAPK to the activation of
prosurvival signals through growth factors and their receptors.
Hence, analogs of naphthoquinone scaffolds may be used to
potentially generate more selective activity. We focused on
activation of neurotrophic receptors to regulate neuronal
health and function after stress or injury (7). Specifically, we
studied mechanisms related to glial cell line–derived neu-
rotrophic factor (GDNF), a growth factor that was tested in
trials for Parkinson’s (8). GDNF therapy has also been proposed
for retinal degenerative diseases and showed early promise in
animal models of retinitis pigmentosa (RP) (9–11). RP is a
blinding condition resulting from the progressive loss of pho-
toreceptors. Since over 300 different mutations (e.g. in the Rho-
dopsin gene) can give rise to the RP phenotype, there is a need
for a broad-spectrum neuroprotective strategy (12).
So far, GDNF therapy has failed clinically. The reasons for
slow therapeutic progress include poor pharmacokinetics, sta-
bility, and distribution. This means it must be given continu-
ously to be efficacious, and the potential for side effects is a
concern.Another problem is related to theway bywhichGDNF
activates trophic signals. GDNF must bind to a receptor GFRa
and only then it can activate a receptor tyrosine kinase RET,
whichmediates the trophic signals. This requirement byGDNF
of a co-receptor narrows the breadth of responding cells to
those that can access both subunits. A small molecule selective
activator of RET, irrespective of GFRa expression, might cir-
cumvent all these therapeutic problems. Moreover, such mol-
ecules could be used as chemical-biology tools to evaluate
RET–GFRa functional interactions.
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In the present work we report the development of novel sub-
stituted naphthoquinones along with their corresponding
quinoline forms and show that they act as selective agonists for
the RET tyrosine kinase receptor, activating the downstream
effectors Akt and Erk. Some agents are agonistic regardless of
whether or not the GFRa1 receptor is present. For other agents,
GFRa1 receptor expression causes biased RET signaling with
differential effects upon pAkt and pErk activation, and this can
be regulated positively or negatively by the reported GFRa1
modulator XIB4035. A GFRa1-independent RET agonist Q525
was neuroprotective in a mouse model of RP, generating trophic
signals in vivowithin theMuller glial cell population, thus validat-
ingRETas a druggable therapeutic target and suggesting potential
utility for therapy of neurodegenerative diseases.
Results
Identification of novel naphthoquinone RET
activators/modulators
All compounds and structures are summarized in Table 1 in
the order that they are mentioned. Biochemical assays revealed
that the chlorinated methoxy 1,4-naphthoquinone Q121 acti-
vated pAkt and pErk inMG87 RET/GFRa1 cells. Q121 induced
RET phosphorylation in a dose-dependent manner (blots were
probed using mAb 4G10 for total pTyr residues) (Fig. 1A).
Compound Q128 with an (–OH) substituting the (–OCH3)
group of Q121 was inactive (Fig. 1A), indicating the functional
relevance of the –OCH3 adduct. These data provide a rationale
for further substitutions of the core structure at this position.
To further evaluate RET phosphorylation byQ121, as well as
its potential requirement of GFRa1 expression (which GDNF
requires), immunoprecipitation experiments were performed.
Phospho-RET was significantly increased by treatment of 100
M.However, inMG87 RET cells lackingGFRa1, there were no
increases in RET phosphorylation detected above background
vehicle control (Fig. 1C). These data indicate that Q121, like
GDNF, requires GFRa1 to signal through RET.
Compounds coded Q101, Q105, Q112, Q141, Q143, Q151,
and Q1047 were then synthesized (see “Materials and Meth-
ods” and supporting text) and evaluated in biochemical
assays. Significant increases in pAkt and pErk were observed
with compounds Q105, Q112, Q141, Q151, and Q1047,
whereas Q101 and Q143 were inactive (Fig. 1C). However,
counterassays using MG87 cells expressing the NGF recep-
tor TrkA tyrosine kinase (instead of RET) showed significant
activation of pAkt and pErk, even though RET is absent. This
indicates that these quinone derivatives lack selectivity
(Fig. 1D).
Despite poor RET selectivity, compounds such as Q151
remained interesting because they induced RET phosphoryla-
tion whether or not the GFRa1 co-receptor was present (Fig.
1E). These data suggest that the modifications to the side chain
of position A (Table 1) allows GFRa1 independence. One con-
cern with these agents is that significant cytotoxicity was
observed in the 1–10 M range when these compounds were
screened via the MTT survival assay; this was therefore
addressed in further analogs.
Chlorine substitution affects potency and toxicity and
generates GDNF-modulating compounds
To address cytotoxicity, we evaluated substitutions of the
chlorine atom at position B (Table 1) because the ring-associ-
ated chlorine can enhance chemical reactivity and oxidative
toxicity (2). CompoundsQ2003 andQ2004, bearing a hydrogen
in place of the chlorine, were prepared.
Biochemical assays revealed these compounds to be signifi-
cantly less potent, with nonsignificant pAkt/pErk activation
even when assayed at a high M concentration range (data not
shown). Moreover, in biological assays measuring cell survival,
both Q2003 and Q2004 displayed weak trophic activity, which
was nonselective and was detectable in MG87 RET/GRFa1 as
well as in MG87 TrkA cells. In MTT assays Q2003 and Q2004
supported cell viability to 8–18% of the survival induced by
optimal growth factor concentrations (GDNF for RET/GRFa1-
expressing cells and NGF for TrkA-expressing cells) (Fig. 1, F
and G).
Although Q2003 and Q2004 lacked potency and selectivity,
they remained interesting because their activity was additive in
MG87 RET/GRFa1 with suboptimal doses of GDNF (Fig. 1F),
and this effect was not observed in MG87 TrkA with subopti-
mal doses of NGF (Fig. 1G). Therefore, although the survival
induced byQ2003 andQ2004 can be RET-independent (i.e. the
compounds afford survival to MG87 TrkA cells), the RET/
GDNF axis is involved in the functional outcome because the
Table 1
Overview and compound structures
Overview and compound structures are shown, listed as they appear to show
Structure–activity relationship progression. Letters A–D denote the positions and
order in which the modifications took place throughout the paper, and the com-
pounds that resulted. The adjacent text on the core structure describes the param-
eters that the modification influenced. Starting from Q121 and Q128, side chain
substitutions at position A generated compounds that activated RET without
GFRa1 expression.Modification at position B through removal of the chlorine atom
generated compounds that were much less potent, although toxicity was improved
and they potentiated GDNF survival. However, A and B modified compounds
exhibited poor selectivity.Modification at position C byNsubstitution yielded com-
pounds with improved selectivity for RET and were pursued in further studies.
Finally, compounds tested with N-substitutions at both positions C and D were
found to be generally inactive.
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agents potentiate GDNF trophic action, but they do not poten-
tiate NGF trophic action.
To assess the basis of toxicity by some compounds, MTT
assays were performed with cells growing in serum to assess
negative effects on growth/survival over 72 h. At 1 M, both
Q2003 and Q2004 (lacking the chlorine) showed no signs of
causing cell death (Fig. 2). In contrast, Q1047, identical to
Q2003 but including the chlorine, was significantly toxic. Tox-
icity was comparable for MG87 RET/GFRa1 and MG87 TrkA
cells, indicating that the toxicity is from a RET-independent
mechanism.
Knowing that the presence of the chlorine is tied with
potency, we designed structural modifications that preserve
that position but reduce toxicity. Synthesis and evaluation of
Q525 showed that is significantly less toxic than Q1047. Q525
was selected for further studies.
Figure 1. Screening and structure–activity relationship of naphthoquinone RET activators. A, compound Q121 and Q128 activity in MG87 RET/GFRa1
cells. Following serum starvation, the cells were exposed for 20 min to vehicle, 10 ng/ml GDNF, or compounds at the indicated micromolar range. The lysates
were collected and probed for pAkt, pErk, and total phosphotyrosine (4G10). Representative Western blotting data are shown. Actin was probed as internal
loading standard. B, representative total RET immunoprecipitation from MG87 RET cells transfected with either GFRa1 or GFP control. Q121 treatment results
in RET phosphorylation at concentrations of 50 and 100 M in the cells expressing GFRa1. Total RET was probed as internal loading standard. For MG76
RET/GFRa1 cells, G represents GDNF as positive control. For MG87 RET/GFP, Ga1 represents GDNF GFRa1 co-treatment, which is needed to induce RET
phosphorylation in these cells lacking GFRa. C, activities of naphthoquinone derivatives. Side-chain modifications generated compounds active in MG87
RET/GFRa1 as demonstrated by the representative Western blotting.D, the naphthoquinone derivatives are also active in MG87 TrkA cells as demonstrated by
the representative Western blotting. E, compound Q151 induces RET phosphorylation in both MG87 RET/GFRa1 and in RET/GFP cells lacking GFRa1. F, MG87
RET/GFRa1 cells in SFM were treated with Q2003 and Q2004 alone or in combination with suboptimal GDNF (GDNF SO, 5 ng/ml). Survival was assessed by MTT
after 72 h. Both compounds had low but significantly trophic activity at a concentration of 1 M. Compounds significantly potentiate suboptimal GDNF. G,
MG87 TrkA cells in SFM were treated with Q2003 and Q2004 alone or in combination with suboptimal NGF (NGF SO, 60 pg/ml). Survival was assessed by MTT
after 72 h. Both compounds had low but significantly trophic activity at a concentration of 1 M but did not potentiate suboptimal NGF. The data are expressed
as percentages of survival S.D. from four experiments, with the respective optimal trophic factor (GF O, 30 ng/ml) standardized to 100% and vehicle to 0%.
*, vehicle versus all treatments; #, suboptimal GF versus optimal GF;, suboptimal GF versus all treatments. One symbol, p 0.05; two symbols, p 0.005; three
symbols, p 0.0005 (Bonferroni-corrected t test).
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In summary, simple side-chain substitutions of the naph-
thoquinone core resulted in RET-activating compounds, and
although lacking RET selectivity the compounds did not
require GFRa1 co-expression. The chlorine is associated
with the potency of the compounds but also with the toxicity.
Removal of the chlorine generated less potent compounds,
and although RET selectivity was still not achieved, the com-
pounds were considerably less toxic and had the ability to
cooperate with GDNF. These observations prompted fur-
ther chemical design of the naphthoquinone core in efforts
to improve RET selectivity.
Quinoline analogs are RET activators with improved selectivity
and GFRa1 independence
To improve upon this first generation of molecules, we syn-
thesized quinoline derivatives bearing identical side chains to
their naphthoquinone counterparts. This effort generated new
chemical entities with a nitrogen at position C (Table 1). These
compounds are chemically distinguished from known inhibi-
tors of protein-tyrosine phosphatases (PTPases), to exclude this
as a possible factor in the poor selectivity of the first-generation
molecules.
Q525 (andQ508) were screened in biochemical assays. Q525
was active in MG87 RET/GFRa1 cells across a broad range of
concentrations and generated large and significant increases in
pAkt/pErk (Fig. 3A; quantified in Fig. 3B). The compound
maintained a high degree of selectivity for RET, because no
significant increases in pAkt and pErk were observed in MG87
TrkA cells (Fig. 3C; quantified in Fig. 3D).
The improved selectivity of the quinoline series (e.g.Q525) is
exemplified by a lack of selectivity in Q1047 (the naphthoqui-
none form of Q525), which activates signals in MG87 TrkA
cells (Fig. 2C). Additionally, analogs Q1041 and Q1048 bearing
a quinoxaline motif with N-substitutions at both positions C
and D (Table 1) were synthesized and found to be inactive at all
concentrations tested. Together, these data suggest that the
N-substitution in the ring system has a significant impact on
compound selectivity, generating agents that maintain RET
activity and GFRa1 independence.
Differential signaling profiles through pAkt and pErk in
combinationwith the GFRa1modulator XIB4035
We used the GFRa1-independent RET agonists as chemical-
biology tools to study the influence of the GFRa1 co-receptor
upon RET signaling.We evaluated the quinone/quinoline pairs
Q1047/Q525 and Q112/Q508 in combination with XIB4035,
which is a reportedGFRa1modulator with no agonistic activity
on its own (19).
Suboptimal doses (10M) ofQ1047 (nonselective agonist) or
Q525 (selective RET agonist) generated low but significant
increases in both pAkt and pErk, comparedwith control vehicle
or to 4 M XIB4035, which did not activate signals (Fig. 4A).
Compared with single treatments, a combination of 4 M
XIB4035  10 M of Q1047 or Q525 resulted in significant
increases of pErk signals (50 and 100%, respectively) (Fig.
4B), whereas pAkt levels were unaffected (Fig. 4C). These
data suggest a RET-mediated pErk bias when GFRa1 is mod-
ulated by XIB4035.
Suboptimal doses (10 M) of Q112 (nonselective agonist) or
Q508 (selective RET agonist) generated low but significant
increases in both pAkt and pErk, comparedwith control vehicle
or to 4 MXIB4035. A combination with 4 MXIB4035 caused
a reduction by 50% of the pAkt that was induced by Q112 or
Q508 alone (Fig. 4C) while leaving pErk unaffected (Fig. 4B).
Hence, a GFRa1 modulator XIB4035 alters the signals
induced by RET agonists, even when these agonists do not
require GFRa1 to signal on their own. In one case (Q1047 or
Q525) it enhances pErk signals but does not affect pAkt, and
in another case (Q112 or Q508) it decreases pAkt signals but
does not affect pErk. The end result for both families of
compounds is a pErk signaling bias; however, this is likely
achieved through different mechanisms that involve a
ligand-mediated regulation of RET by the GFRa1 receptor.
Also, it is of interest that N-substitution in the ring of struc-
turally related quinone/quinoline pairs does not affect regu-
lation of signaling by XIB4035.
RET activators are not inhibitors of protein-tyrosine
phosphatases
Several naphthoquinones have been reported as inhibitors of
PTPases, somenonselective (3) and somewith a degree of selec-
tivity (4). RET activation could potentially stem from inhibition
of PTPases, and we evaluated this possibility.
Select compounds were tested in assays of PTPase activity to
evaluate their impact upon the enzymatic activity of five
PTPase enzymes (LAR, PTP-sigma, PTP-1B, MKPX, and
SHP-1) as described (4). The compounds did not affect the
activity of purified PTPases compared with DMSO vehicle,
whereas the positive control sodium orthovanadate showed
significant inhibition of80% (Table 2). The 40 M compound
concentrations evaluated in these PTPase assays are at least
3-fold higher than the compound concentrations that induce
biological signals in cultured cells and likely much higher than
compound concentrations inside the cell, where PTPases are
present.
In particular we note lack of inhibition by the quinone/quin-
oline pairs Q1047/Q525 and Q112/Q508, neither of which
Figure 2. Chlorine substitution affects toxicity and directs lead com-
pound development. MG87 RET/GFRa1- and TrkA-expressing cells were
exposed to 1 M compounds in regular growth media and assessed by MTT.
Q2003 and Q2004 bearing a hydrogen in place of the chlorine were not toxic,
indistinguishable from vehicle control (Veh.). However, Q1047, the chlorine-
containing analogue of Q2003, showed significant signs of toxicity under the
same conditions. Additionally, the lack of toxicity observed by Q525 demon-
strated that the chlorine could be maintained and directed the development
of more potent, RET-selective leads. The comparable toxicity between both
cell lines indicated that the origin of the toxicity is not due to RET overactiva-
tion but rather a generalized mechanism.
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affected any of the five PTPases tested. Moreover, the fact that
XIB4035 (a GFRa1 modulator with no reported link to
PTPases) regulates pErk signals induced by Q1047/Q525 and
Q112/Q508 (Fig. 4) is consistent with the notion that these
agents are not PTPase inhibitors.
Q525 is neuroprotective by activation ofMüller glial cells
We selected Q525 for pharmacological evaluation in vivo in
the transgenic mutant RHOP347S mice (expressing a mutant
rhodopsin gene that causes retinitis pigmentosa). These mice
undergo rapid photoreceptor apoptosis that peaks in vivo
between postnatal days 18 and 22 (20). The rate of photorecep-
tor apoptosis is fully replicated ex vivo in cultured whole retinal
explants from these mice, allowing rapid testing of many com-
pounds and doses.
Retinal explants were prepared from 18-day-old mice and
incubated for 24 h with either compounds or vehicle, followed
by quantification of TUNEL staining. Representative confocal
images of the central retinal region are shown (Fig. 5A). Q525 at
a 20Mdose affords robust preservation of the photoreceptors,
as indicated by a 40% reduction in TUNEL cells in this layer
(Fig. 5B). In controls, the inactive compound Q143, assayed
previously (Fig. 1C), was indistinguishable from vehicle-treated
retinas. The data support the notion that RET activation by
Q525 may be a disease-modifying strategy for degenerative
conditions like RP.
To understand the neuroprotectivemechanism of action, we
studied activation of biochemical pathways in the retina. Mice
(n  3) received intravitreally administered test compound in
one eye and control vehicle in the contralateral eye. Eyecups
were collected 1 h later and examined by immunohistochemis-
try to quantify pErk and pAkt signals. The results show that the
Q525-treated eyes had elevated levels of pErk and pAkt by 1.8-
and 2.0-fold, respectively, whereas no significant elevations in
pErk or pAkt were observed in animals injected with the inac-
tive Q143 (Fig. 5, E and F). This is consistent with biochemical
assays using cell lines (Figs. 1 and 3). The pAkt and pErk signals
co-localized with the Müller cell marker CRALBP. This indi-
cates that the Müller glial cells are among the primary cellular
targets for the RET agonists, and these cells are known to
express RET and to support the health of photoreceptors.
Discussion
Wediscovered a series of new chemical entities, naphthoqui-
none/quinoline derivatives with agonistic activity at the RET
receptor tyrosine kinase. Employing them as biological tools,
we explored functional regulation between RET and its co-re-
ceptor GFRa1. A summary of screening and biochemical data is
provided in Table 3.
We demonstrated that although these agents do not require
the presence of GFRa1, their signaling profiles can be nuanced
by the presence and bound state ofGFRa1. The regulatory func-
tions that the GFRa subunits exert over RET provide additional
points to consider when using RET agonists for therapy. We
also showed the neuroprotective efficacy of a lead agent, Q525,
Figure 3. Development of lead quinoline derivatives. A and B, biochemical screening of Q525 in MG87 RET/GFRa1 cells. The compound generated large
increases in pAkt/pErk within the 5–20 M range. Western blotting data were quantified from three experiments and are expressed as means S.D. versus
vehicle (V or Veh), standardized to 100%. For pAkt; *, p 0.05; **, p 0.005; ***, p 0.0005. For pErk: #, p 0.05, Dunnett’s test. C and D, counter screens with
Q525 were performed in MG87 TrkA cells. Only slight increases in pAkt/pErk were observed within the same concentration range. For comparison, the poorly
selective Q1047 bearing an identical side chain is also shown. The results were quantified from three experiments and are expressed as means S.D. versus
vehicle, standardized to 100%. For pAkt: **, p 0.005. For pErk: #, p 0.05, Dunnett’s test. G, positive control GDNF; N, NGF.
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in a model of RP neurodegeneration; further validating RET as
a potential therapeutic target.
Screening and optimization of novel derivatives
The finding that the relatively simple naphthoquinone Q121
was a weak RET agonist but required GFRa1 expression was sur-
prising, given its extremely small size compared with GDNF and
the large surface of interactions of the receptor complex. Large
growth factors like GDNF are typically envisioned as mediating a
“bridge” between receptor components, bringing them in close
proximity through multiple contact points and stabilizing an
active conformation. It is unlikely that smallmolecules are capable
of fully replicating this. The literature suggests that RET and
GFRa1 associate in a ligand-independent manner (21), and it is
therefore possible that our agents cause RET conformational
changes through a preformed receptor complex.
The substitutionof themethoxygroup for ahydroxyl abrogated
RET activity and clearly implicated this position for synthesis of
analogs. However, further screening of these naphthoquinone
derivatives, althoughbiochemically interesting,didnotpossess the
RETselectivityworthyofpursuit. It isunclearhowthecompounds
activate pAkt and pErk in non–RET-expressing cells, but the
potential molecular targets of the quinone family are broad. Their
GFRa1 independence was unexpected but highlights one of the
many strengths in small molecule development in that minor
structural modifications can have major biochemical
impacts. This is again reflected by the impact of the chlorine
to hydrogen substitution, yielding mildly prosurvival,
GDNF-modulating effects in vitro.
To differentiate the core structure from those reported previ-
ously as being phosphatase inhibitors (4), we made additional
modifications to the ring system, generating novel quinolinedio-
nes which demonstrated much improved characteristics. The
quinoline scaffold has a rich pharmacological background, partic-
ularly inregard toanti-cancer therapeutics (22), and in facta family
of RET kinase inhibitors with this motif exists (23). Others also
reported a series of quinolines with neurotrophic activity (24), but
their molecular target and signals remain unknown.
Significance of GFRa1-dependent signaling bias
Biased signaling is a relatively new concept in the field of
pharmacology, and even more recent is the notion that this
property can be exploited to improve therapeutic efficacy
(25). Some of the first biased ligands were synthetically
derived, and it was largely unknown whether this type of
signaling occurred endogenously as an added regulatory
mechanism. The chemokines and their receptors are one
such example, revealing the presence and utility of signaling
bias at the biological level as a means to fine-tune responses
to a wide array of stimuli (26).
Our findings with the compounds in combination with
XIB4035 demonstrate a unique aspect of ligand bias working
through a co-receptor, and there are few examples of this in the
literature (27, 28). The compounds reported display a balanced
activation of both pAkt and pErk pathways through RET by
themselves but become biased in the presence of aGFRa1mod-
ulator. In contrast GDNF activation of the RET tyrosine kinase
functions solely in conjunctionwith amembrane-bound or sol-
uble co-receptor GFRa, a feature of this receptor that is con-
served among vertebrates (29).
It is tempting to speculate that GFRas may be a gatekeeper
of signaling bias. Through shifting their expression levels
and patterns, GFRas may allow a single ligand to generate a
series of orchestrated responses within the same tissue.
Ligand–GFRa complexes may also control RET distribution
into and out of lipid rafts, as is the case when comparing
Figure 4. Differential signaling through pAkt/pErk is mediated by
XIB4035-inducedmodulation of GFRa1. A, representative blots taken from
separate experiments showing pAkt and pErk signaling of compounds
Q1047, Q525, Q112, and Q508 with or without XIB4035 pretreatment. V, vehi-
cle. G, positive control GDNF. B, quantification of pErk signals of compounds
Q1047, Q525, Q112, and Q508 in combination with the GFRa1 modulator
XIB4035. XIB4035 pretreatment did not affect pErk signals induced by Q112
and Q508. However, Q1047 and Q525 signals were significantly increased. The
data are expressed as means  S.D. from five experiments standardized to
compound alone, which was set at 100%. *, p 0.05; ***, p 0.0005, Bonfer-
roni-corrected t test. C, quantification of pAkt signals of compounds Q1047,
Q525, Q112, and Q508 in combination with the GFRa1 modulator XIB4035.
XIB4035 pretreatment did not affect pAkt signals induced by Q1047 and
Q525. However, Q112 and Q508 signals were significantlydecreased. The data
are expressed as means  S.D. from five experiments standardized to com-
pound alone, which was set at 100%. *, p  0.05; **, p  0.005, Bonferroni-
corrected t test.
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persephin versus GDNF (30), and this could dictate which
adaptor proteins are most accessible to the activated kinase.
It is also known that receptor–receptor interactions on the
membrane can create allosteric regulatory sites at which
ligands may bind to alter the functional outcome (31). Stud-
ies with constitutively active p75 mutants reveal that very
slight changes in subunit positioning affect the resulting sig-
naling profile and therefore suggest that different ligands
could stabilize unique conformations of the receptor com-
plex to drive signaling bias (32).
Although we did not address this within the present work,
soluble GFRas can also be liberated from the membrane sur-
face, and the biological roles of this process are understudied
but are likely to be diverse (33–35). This could provide another
way for bias control via the RET–GFRa complex.
Additionally, there may be other endogenous ligands such as
GDF15 (36) or ligands of GFRa that can modulate biased signals
through RET to mediate important processes. In that regard, it
wouldbe interesting touseGFRamodulators in combinationwith
RETagonists, butunfortunatelyXIB4035cannotbeused in vivo in
the retina because of poor solubility and high toxicity (19). There
are GFRa modulators under development (e.g. XIB4035 analogs)
that eventually can be tested to answer this question.
Our findings have therapeutic relevance, especially in disease
where RET expression remains stable, but GFRa levels vary
considerably (37, 38). A RET agonist may provide benefits in
some diseases where dynamic changes occurring at GFRa in
vivo are difficult to assess or control. As more work is done to
validate RET and its co-receptors as targets, the ability to take
advantage of signaling bias to yield highly specific outcomes
with lower side effects may be a promising strategy.
Materials andmethods
Commercially available compounds
Compounds Q121 (CAS registry no. 6956-96-3), Q128 (CAS
registry no. 1526-73-4), and Q151 (CAS registry no. 84348-
90-3) are known and described.
Chemistry and synthesis of novel naphthoquinone derivatives
All chemicals were purchased from Aldrich, J&K, or Otava.
The reactionsweremonitored byTLCusing aluminum-backed
silica gel plates (Aldrich, silica gel matrix with fluorescent indi-
cator), products visualized under UV light (254 and 365 nm).
Flash chromatography purifications were performed in col-
umns using SilicaGel 60A, 230–400mesh (ACP).NMRspectra
were recorded on Bruker 400MHz spectrometer. Mass spectra
were obtained with a Bruker mass spectrometer AmaZon SL
direct infusion and Bruker UltraFlextreme MALDI-TOF.
Chemical synthesis, MS, and NMR spectra and other charac-
terization of the compounds are presented in the supporting
information.
Cell lines
MG87 RET are murine MG87 fibroblasts stably transfected
with RET proto-oncogene cDNA (13) and were cultured in
DMEM containing 10% FBS, 2 mM L-glutamine, 10mMHEPES,
100 units/ml penicillin/streptomycin, and 2 g/ml puromycin.
MG87 RET cells were transfected with a GFRa1 cDNA con-
struct containing Blasticidin resistance to generate the MG87
RET/GFRa1 cell line and were cultured in the same medium
with the addition of 5 g/ml Blasticidin S. MG87 TrkA cells
were transfected with human TrkA cDNA and cultured in
DMEM with 10% FBS supplemented with 250 g/ml G418.
MG87RET/GFRa1 cell lines were stably transfected with the
PathDetect Elk-1 system (Stratagene) harboring Luciferase
reporter under the control of Erk activity. The cells were cul-
tured in DMEM, 10% FBS, 15 mM HEPES, pH 7.2, 100 g/ml
normocin (Invivogen), 2g/ml puromycin (14). Growth factors
GDNF and NGF were purchased from Peprotech (catalog nos.
450-10 and 450-01).
RET phosphorylation assays
Phosphorylation of RETwas assessed as previously described
(15). MG87 RET cells were plated on 35-mm tissue culture
dishes, left to attach to the surface overnight, and then trans-
fected with 4g/dish of GFRa1-expressing plasmid using Lipo-
fectamine 2000 (Invitrogen) for DNA delivery as described by
manufacturer. The next day the cells were starved for 4 h in
serum-free DMEM containing 15 mM HEPES, pH 7.2, and
treated with 1% DMSO vehicle, compounds, or GDNF (200
ng/ml) for 15 min. The cells were lysed using radioimmune
precipitation assay–modified buffer (50 mM Tris-HCl, pH 7.4,
150mMNaCl, 1mMEDTA, 1%Nonidet P-40, 1%Triton X-100,
10% glycerol, EDTA-free EASYpack, protease inhibitor mix-
ture (Roche), 1 mM Na3VO4, 2.5 mg/ml of sodium deoxy-
cholate). Cleared lysates were immunoprecipitated with 2
g/ml of anti-RET C-20 (Santa Cruz Biotechnology, Inc.,
sc-1290), and the beads were conjugated with protein G
(Thermo Fisher Scientific catalog no. 10004D). Eluted samples
were resolved on 7.5% SDS-PAGE, and total phosphotyrosine
residues were then probed in Western blots using the 4G10
antibody (Millipore). To confirmequal loading, themembranes
Table 2
Ability of select compounds to inhibit phosphatases
Select compounds were screened for their ability to inhibit the phosphatases LAR, Sigma, PTP1B, MKPX, and SHP-1. The data are shown as the percentages of inhibition
relative to DMSO control. Sodium orthovanadate (Na3VO4) was used as positive control as a broad-spectrum PTP inhibitor.
Q number LARD1D2 SigmaD1D2 PTP1B MKPX SHP-1
105 97 98 77 99.5 87
112 91.5 96.5 121.5 97 80
121 96.5 97.5 93 98 90
143 96 99 101 96.5 103.5
508 72 71 92.5 96.5 91
525 97.5 99.5 96 99 94
Na3VO4 16.5 24 4 5
DMSO 99 97.5 99.5 99 93
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were reprobed with anti-RET C-20 antibodies (1:500, Santa
Cruz Biotechnology, Inc.).
pAkt, pErk1,2 biochemical studies
The cells were seeded onto 6-well plates (0.4  106 cells/
well) and cultured overnight. The cells were serum-starved for
2 h and treated with vehicle, compounds, or growth factor (GF)
as indicated in the text (generally for 20 min). Cell lysates were
prepared (20mMTris-HCl, pH 7.5, 137mMNaCl, 2 mM EDTA,
1%Nonidet P-40 containing a protease inhibitormixture). Pro-
tein was quantified in cleared lysates using the Bradford assay
(Bio-Rad). After SDS-PAGE, Western blotting was evaluated
Figure 5. Q525 is neuroprotective ex vivo in a mouse model of retinal degeneration and activates trophic signals in Muller glial cells. A,
representative confocal images of retinal flat mounts following treatment with Q525 and Q143. Freshly dissected retinas from 18-day-old RHOP347S
mice were incubated in culture medium for 24 h: one retina with the indicated compounds and the contralateral retina of the same mouse with vehicle
control (e.g. each individual had its own internal control). The tissues were processed for TUNEL staining and flat-mounted. 12 images were taken per
retina and quantified semiautomatically. B, quantification of TUNEL-positive (pos.) cells after treatment. Cell counts from n  3 mice/group were
standardized versus vehicle control (Veh). Q525 treatment affords a significant reduction in TUNEL staining, whereas Q143 treatment was comparable
to vehicle. *, p 0.05, Student’s t test. C and D, images of retinal sections stained for pErk and pAkt following intravitreal injection of compound Q525
in vivo. Eyecups were collected 1 h after injection. Significant increases in staining for pErk and pAkt co-localized with the Muller cell marker CRALBP,
suggesting activation within the glial population. RGC, retinal ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar, 25 m. E,
pErk quantification of Q525 and Q143 retinal sections (n  3/group) expressed as the fold change in pixel area over vehicle  S.D. ***, p  0.0005,
Student’s t test. F, pAkt quantification of Q525 and Q143 retinal sections (n 3/group) expressed as the fold change in pixel area over vehicle S.D., *,
p  0.05, Student’s t test. DAPI, 4,6-diamidino-2-phenylindole.
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with the primary antibodies pAkt, pErk1,2 (Cell Signaling, cat-
alog nos. 4060 and 4370), or Actin control for loading (Sigma–
Aldrich, catalog A2066). Signals were developed usingWestern
Lightning Plus ECL (PerkinElmer), and films were scanned and
quantified using ImageJ software.
Phosphatase inhibition screens
PTP activity/inhibition assays are as we reported previously
(4). The tagged catalytic domain or the full length of the follow-
ing phosphatases were used for the screen: GST–PTP1B aa
1–321, GST–LAR–D1D2, GST–Sigma–D1D2, GST–MKPx aa
1–184, and His-SHP-1 aa 1–595. Enzyme reactions were per-
formed in assay buffer 50 mM HEPES, pH 7.0, for PTP1B, LAR,
Sigma, and MKPx and buffer 50 mM Bis-Tris, pH 6.3, 2 mM
EDTA for SHP-1. DiFMUP (Invitrogen) was used as substrate
for all assays, in black 96-well plates (Corning) in a final volume
of 100 l at 25 °C. The reaction was monitored by measuring
the fluorescence (excitation wavelength, 358 nm; emission, 455
nm) with the Varioskan plate reader (Thermo Electron). For
the kinetic assays, fluorescence was monitored over 10 min in
30-s intervals, and rates were calculated in fluorescent units/
min. Km was determined from rates at various substrate con-
centrations usingMichaelis–Menten equation from GraphPad
Prism software. A substrate concentration equivalent to theKm
value for each PTPwas used for the screening of the compound.
Inhibitors were diluted in DMSO, and then a dilution to 10 M
or 40 M was made in assay buffer. Controls contain 1–2%
DMSO final. Phosphatases and compounds were preincubated
2–5 min prior to addition of DiFMUP for enzyme inhibition
quantification.
Cell survival assays
Cell survival was measured by the MTT assay (Sigma–
Aldrich) using optical density readings as the end point. 2000–
5000 cells were plated in 96-well format in SFM containing
0.03% FBS (HCell-100, Wisent). The indicated test agents or
DMSO vehicle were added to the wells. The respective GFs (30
ng/ml GDNF for MG87 RET/GFRa1 and 30 ng/ml NGF for
MG87 TrkA) at optimal concentrations were added as control.
Assay lengthwas typically 72 h because this time point yields an
optimal signal-to-noise ratio between vehicle and growth factor
controls. The assays were repeated at least three times (each
assay n 4–6wells/condition).MTToptical density data were
standardized to growth factor  100%, and SFM  0%, using
the following formula: (ODtest 	 ODSFM)  100/(ODGF 	
ODSFM).
Animalmodels
All animal procedures respected the institutional animal care
and use committee guidelines for use of animals in research and
protocols approved by McGill University Animal Welfare
Committees. All animals were housed with a 12-h dark–light
cycle with food and water ad libitum. We used the RHOP347S
transgenic mouse (expressing the human Rhodopsin mutated
at amino acid position 347) in a C57BL/6J (B6) background
(kindly donated by Dr. T. Li). This model of RP faithfully repli-
cates the features of disease progression in humans.
Retinal organotypic cultures
Whole eyes were enucleated, and whole retinas dissected
from WT and RHOP347S mice at postnatal day 18 were used
for organotypic culture experiments. Following enucleation,
the eyes were placed in a Petri dish with PBS. The cornea was
perforated and cut away along the ora serrata, leaving room to
remove the lens.Whole intact retinaswere then freely dissected
away from the sclera and immediately transferred into 24-well
plates containing 500 l of culture medium (DMEM/Ham’s
F-12 supplemented with 10 mM NaHCO3, 100 g/ml transfer-
rin, 100 M putrescine, 20 nM progesterone, 30 nM Na2SeO3,
0.05 mg/ml gentamicin, 2 mM L-glutamine, and 1 mM sodium
pyruvate). Under sterile conditions, the medium was gently
removed, replaced with fresh medium containing the treat-
ments or controls, and incubated at 37 °C and 5% CO2 for 24 h.
The compounds were tested at a concentration of 20 M. Cell
grade DMSO was used for vehicle treatments and was 0.5% by
volume. The retinas were then used for TUNEL staining.
Table 3
Summary of pharmacological profiles
Comparison of signaling (maximal efficacy of activation of Akt/Erk in RET-expressing cells) by the compounds relative to each other and toGDNF. Potency is not indicated
(e.g. GDNF is nM, and compounds are M). RET selectivity was gauged by quantification of signaling in cells not expressing RET but expressing other RTKs (negative
Akt/Erk activation is wanted). Culture of various cell types with the compounds in serum-containing media gauged general toxicity, and culture in serum-free conditions
gauged accelerated or delayed cell death. The use of various cell types in such assays evaluated RET dependence. Q525 is highlighted as a potential lead with the best balance
overall. , low/poor; , moderate; , high; —, not tested/not applicable. The summary illustrates the interplay that exists between the different parameters and
profiles and the challenges of choosing a lead agent.
Test Potency RET selectivity GFRa1-dependent Toxicity
GDNF   Yes —
121   Yes 
128   — 
101   — 
105   No 
112   No 
141   No 
143  — — 
151   No 
1047   No 
2003   — 
2004   — 
508   No 
525   No 
1041  — — —
1048  — — —
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TUNEL staining
Staining was performed using the DeadEnd Fluorometric
TUNEL system (Promega) as per manufacturer’s instructions
and as described by us (16, 17). RHOP347S retinas in culture
were first fixed in 4% paraformaldehyde in PBS and kept at 4 °C
overnight, followed by permeabilization using 2% Triton-X in
PBS and refixed in paraformaldehyde for 30 min. Retinas were
incubatedwith 50l of equilibration buffer for 20min and then
25l of terminal deoxynucleotidyl transferase reactionmixture
for 2.5 h at 37 °C, and the reaction was then terminated. The
retinas were washed and mounted using Vectashield with 4,6-
diamidino-2-phenylindole. For image acquisition (17, 18), the
retinas were divided into four quadrants, and three pictures
with a 20 objective were taken in each area (central, mid,
peripheral) for a total of 12 images of the outer nuclear layer per
retina. Total TUNEL-positive cells were counted in each image
semiautomatically (ImageJ). Counts were verified by at least
one other person blinded to the experimental conditions. Ret-
inal flat mounts from WT mice (where there is no mutation-
driven photoreceptor death) were used as negative controls.
Immunohistochemistry
Stainingwas performed as described by us (17). After enucle-
ation, the cryoprotected eyes were mounted in Tissue-TEK
(Sakura), and cryostat sections were cut andmounted onto gel-
atin-coated glass slides. Sections (14 m thick) were incubated
in PBS containing 3% normal goat serum, 0.2% Triton X-100,
and 3% BSA for 2 h. The retinal sections were incubated over-
night at 4 °C with primary antibody (1:250 p-MAPK, Cell Sig-
naling no. 4370; 1:250 p-Akt, Cell Signaling no. 4060; 1:400
CRALBP, Abcam ab183728). The sections were rinsed and
incubated with secondary antibody for 1 h at room tempera-
ture. Then the sectionswerewashed andmounted (Vectashield
mounting medium with 4,6-diamidino-2-phenylindole).
Image acquisition (fluorescencemicroscopy) and data
analysis
Pictures were taken as Z-stacks of confocal optical sections
using a Leica confocal microscope at a 20 objective. The
images were equally adjusted using Adobe Photoshop CS 8.0 to
remove background signals. For each experimental condition, a
minimum of six images were acquired from three sections cut
from different areas of the retina (n  3 retinas/group). The
area of the profiles of the cells expressing pErk and pAkt was
measured using ImageJ software.
Intravitreal injections
Briefly, the mice were anesthetized with isoflurane delivered
through a gas anesthetic mask. The treatments were delivered
using a Hamilton syringe. Injections were done using a surgical
microscope to visualize the Hamilton entry into the vitreous
chamber and confirm delivery of the injected solution (3 l of a
2 mM stock solution). After the injection, the syringe was left in
place for 30 s and slowly withdrawn from the eye to prevent
reflux. In each animal, the right eye was injected with the test
agents (experimental eye), and the left eye was untreated (inter-
nal control).
Statistical analyses
The quantitative data were subjected to statistical analyses
usingGraphPadPrism5 software and are presented asmeans
S.D. for all studies. The differences between groups were deter-
mined by analysis of variance (multiple groups) followed by
Dunnett’s or Bonferroni corrections as indicated in the figure
legends. Student’s t tests were performed to compare two
groups. p values below 0.05 were considered to indicate statis-
tically significant differences between groups.
Author contributions—S. J. and H. U. S. conceptualization; S. J.,
Y. S., and H. N. data curation; S. J., Y. S., and H. N. formal analysis;
S. J., Y. S., and H. N. investigation; S. J. writing-original draft; S. J.,
Y. S., M. S., and H. U. S. writing-review and editing; Y. S. and H. N.
validation; H. N. methodology; M. S. and H. U. S. supervision; M. S.
and H. U. S. funding acquisition; H. U. S. project administration.
Acknowledgments—Weare thankful toDr.Michel Tremblay and Isa-
belle Aubry (McGill University) for the protein-tyrosine phosphatase
assays.
References
1. Widhalm, J. R., and Rhodes, D. (2016) Biosynthesis and molecular actions
of specialized 1,4-naphthoquinone natural products produced by horti-
cultural plants. Hortic. Res. 3, 16046 CrossRef Medline
2. Bolton, J. L., and Dunlap, T. (2017) Formation and biological targets of
quinones: cytotoxic versus cytoprotective effects. Chem. Res. Toxicol. 30,
13–37 CrossRef Medline
3. Klotz, L. O., Hou, X., and Jacob, C. (2014) 1,4-naphthoquinones: from
oxidative damage to cellular and inter-cellular signaling. Molecules 19,
14902–14918 CrossRef Medline
4. Perron,M.D., Chowdhury, S., Aubry, I., Purisima, E., Tremblay,M. L., and
Saragovi, H. U. (2014) Allosteric noncompetitive small molecule selective
inhibitors of CD45 tyrosine phosphatase suppress T-cell receptor signals
and inflammation in vivo.Mol. Pharmacol.85, 553–563CrossRefMedline
5. Wang, L., Li, Z., Zhang, X., Wang, S., Zhu, C., Miao, J., Chen, L., Cui, L.,
andQiao, H. (2014) Protective effect of shikonin in experimental ischemic
stroke: attenuated TLR4, p-p38MAPK, NF-B, TNF- and MMP-9 ex-
pression, up-regulated claudin-5 expression, ameliorated BBB permeabil-
ity. Neurochem. Res. 39, 97–106 CrossRef Medline
6. Yuan, J. H., Pan, F., Chen, J., Chen, C. E., Xie, D. P., Jiang, X. Z., Guo, S. J.,
and Zhou, J. (2017) Neuroprotection by plumbagin involves BDNF-TrkB-
PI3K/Akt and ERK1/2/JNK pathways in isoflurane-induced neonatal rats.
J. Pharm. Pharmacol. 69, 896–906 CrossRef Medline
7. Josephy-Hernandez, S., Jmaeff, S., Pirvulescu, I., Aboulkassim, T., and
Saragovi, H. U. (2017) Neurotrophin receptor agonists and antagonists as
therapeutic agents: an evolving paradigm. Neurobiol. Dis. 97, 139–155
CrossRef Medline
8. Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws,
E. R., Jr., Lozano, A.M., Penn, R. D., Simpson, R. K., Jr., Stacy,M.,Wooten,
G. F., and ICVGDNF Study Group (2003) Randomized, double-blind trial
of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60,
69–73 CrossRef Medline
9. Frasson, M., Picaud, S., Léveillard, T., Simonutti, M., Mohand-Said, S.,
Dreyfus, H., Hicks, D., and Sabel, J. (1999) Glial cell line-derived neu-
rotrophic factor induces histologic and functional protection of rod pho-
toreceptors in the rd/rd mouse. Invest. Ophthalmol. Vis. Sci. 40,
2724–2734 Medline
10. Touchard, E., Heiduschka, P., Berdugo, M., Kowalczuk, L., Bigey, P., Cha-
hory, S., Gandolphe, C., Jeanny, J. C., and Behar-Cohen, F. (2012) Non-
viral gene therapy for GDNF production in RCS rat: the crucial role of the
plasmid dose. Gene Therapy 19, 886–898 CrossRef Medline
11. García-Caballero, C., Lieppman, B., Arranz-Romera, A., Molina-Mar-
tínez, I. T., Bravo-Osuna, I., Young, M., Baranov, P., and Herrero-Vanrell,
Neuroprotection by RET agonistic small molecules
J. Biol. Chem. (2020) 295(19) 6532–6542 6541
R. (2018) Photoreceptor preservation induced by intravitreal controlled
delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice.
Mol. Vis. 24, 733–745 Medline
12. Baranov, P., Lin, H., McCabe, K., Gale, D., Cai, S., Lieppman, B., Morrow,
D., Lei, P., Liao, J., and Young, M. (2017) A novel neuroprotective small
molecule for glial cell derived neurotrophic factor induction and photo-
receptor rescue. J. Ocul. Pharmacol. Ther. 33, 412–422 CrossRef Medline
13. Eketjäll, S., Fainzilber, M., Murray-Rust, J., and Ibáñez, C. F. (1999) Dis-
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